NIH SBIR/STTR Grants 2026: Phase I $323K, Phase II $2.15M, Receipt Cycles, and the SEED On-Ramp
The National Institutes of Health (NIH) runs the second-largest SBIR budget of any federal agency, and for biotechnology, medical-device, diagnostics, and digital-health startups it is the single most important source of non-dilutive capital in the country. It is also the most structurally distinctive: NIH does not use one application or one deadline. It funds through 24 Institutes and Centers (ICs), on three standing receipt cycles a year, with each Institute setting its own funding cutoff. The companion STTR program adds a university-partner requirement. This guide names the 2026 dollar guidelines, walks the funding ladder from the SEED on-ramp through Phase IIB, and surfaces the failure modes that sink first-time NIH applications. To screen your company's fit before you write a single specific aim, run our NIH funding finder filtered by research area.
- Who this is for: U.S. for-profit small businesses (under 500 employees) in biotech, medtech, diagnostics, digital health, or drug development, including pre-revenue startups.
- What is eligible: Health-related feasibility (Phase I) and full development (Phase II) research; STTR additionally requires a nonprofit research-institution partner doing at least 30 percent of the work.
- How to apply: Register in SAM.gov and eRA Commons, identify the funding Institute and its program officer, then submit through Grants.gov before a standard receipt date.
Table of contents
- What is the NIH SBIR funding ladder?
- How much is an NIH SBIR grant in 2026?
- Which NIH Institutes fund the most SBIR?
- When are the NIH SBIR receipt dates?
- What is the NIH SEED on-ramp?
- How do you apply for an NIH SBIR grant?
- Why do NIH SBIR applications get rejected?
- Frequently asked questions
- Bottom line
What is the NIH SBIR funding ladder?
The NIH SBIR funding ladder is the sequence of award stages a health startup can climb, from a first-time on-ramp through commercialization support. Unlike a single grant, the ladder lets a company stack non-dilutive capital across years, and understanding the rungs is what separates founders who win one grant from those who build a fundable company on federal money. Each rung has its own eligibility gate.
-
SEED on-ramp + Phase Iup to $323,090
The entry rung. Phase I funds feasibility research over 6 months to 2 years. NIH SEED resources and selected on-ramp programs help first-time applicants build a competitive first submission. Pre-revenue startups routinely enter here.
-
Phase IIup to $2,153,927
The development rung. Open to Phase I awardees (or Fast-Track applicants submitting both phases at once). Phase II funds full R&D over 1 to 3 years and is scored heavily on commercialization potential.
-
Phase IIB / competing renewalInstitute-set
The bridge rung. Several Institutes offer Phase IIB competing-continuation funding to close the gap between Phase II results and market entry, often tied to matching third-party investment.
-
Commercialization supportNon-grant
The exit rung. NIH commercialization programs, including I-Corps at NIH and the Commercialization Readiness Pilot where offered, plus the Niche Assessment Program, help awardees reach customers, investors, and regulatory milestones without additional core SBIR cash.
How much is an NIH SBIR grant in 2026?
An NIH SBIR grant in 2026 is governed by SBA statutory guidelines that NIH publishes: $323,090 for Phase Iverified 2026-05-29 and $2,153,927 for Phase IIverified 2026-05-29, per the NIH SEED program guidance. The critical nuance is that these are guidelines, not absolute ceilings. Individual NIH Institutes and Centers can set their own budget limits below the guideline, and NIH holds a waiver from the U.S. Small Business Administration to allow larger awards for specific approved topics. The standing instruction from NIH is explicit: contact the program official before submitting any budget that exceeds the published amounts.
One more figure matters: the payline. Each Institute sets and publishes its own payline, and SBIR/STTR paylines move with annual appropriations. A score that misses one Institute's payline might have funded at another, which is why Institute selection is a strategic decision, not an afterthought.
Which NIH Institutes fund the most SBIR?
An NIH Institute or Center is one of 24 mission-specific funding units within NIH, each with its own research priorities, budget, and SBIR funding considerations. Because NIH uses a single standing application route rather than topic solicitations, your job is to route your proposal to the Institute whose mission and budget best fit your technology. The matrix below summarizes how the largest small-business funders approach SBIR; consult each Institute's SEED funding-considerations page for current specifics.
| Institute / Center | Best-fit technology | SBIR posture |
|---|---|---|
| NCI (National Cancer Institute) | Oncology diagnostics, therapeutics, devices | Large SBIR budget; runs SBIR Development Center and contract solicitations |
| NIAID (Allergy & Infectious Diseases) | Vaccines, antimicrobials, diagnostics | High-volume SBIR funder; topic-aligned interest areas |
| NHLBI (Heart, Lung, Blood) | Cardiopulmonary devices, digital health | Strong device and digital-health portfolio |
| NINDS (Neurological Disorders) | Neurotech, neurodiagnostics | Publishes SBIR/STTR paylines; device-friendly |
| NIA (Aging) | Aging tech, dementia care, AgeTech | Active small-business and AgeTech programming |
| NIDA / NIAAA (Drug Abuse / Alcohol) | Behavioral health, addiction tools | Dedicated SBIR/STTR funding pages and program staff |
When are the NIH SBIR receipt dates?
NIH SBIR and STTR receipt dates are the three standard due-date cycles NIH runs each year for new applications, historically clustered around early September, early January, and early April. The next standard receipt date in 2026 is September 5, 2026verified 2026-05-29. The standing cycle is the backbone, but some Institutes layer topic-specific notices of funding opportunity (NOFO) with their own dates, so the rule is to confirm the date in the exact opportunity you apply to. The principal investigator (PI) employment rules also differ between SBIR and STTR, which shapes who can lead the project.
Complete SAM.gov and eRA Commons registration, identify the funding Institute, and email a program officer to confirm fit. Registration is the longest lead-time item.
Draft and circulate the one-page specific aims; this is the document program officers will react to and the spine of the whole application.
Write the research strategy, commercialization plan, and a budget within the statutory guideline unless a waiver applies.
Submit through Grants.gov and validate in eRA Commons before the standard receipt date (next: September 5, 2026), with buffer for the error-correction window.
Study-section peer review, then Advisory Council review. Funding decisions follow the Institute payline for the fiscal year.
What is the NIH SEED on-ramp?
NIH SEED is the Small Business Education and Entrepreneurial Development office, the part of NIH dedicated to helping small businesses navigate and win SBIR and STTR funding. The SEED website publishes the canonical program guidance, the Institute-by-Institute funding considerations that tell you which Institute funds what, and entrepreneur-support resources aimed at first-time and underrepresented applicants. For any founder approaching NIH for the first time, SEED is the correct starting point, ahead of Grants.gov and ahead of any third-party consultant.
SEED also administers and points to on-ramp programs that lower the barrier for new applicants, including the I-Corps at NIH entrepreneurial training program and application-assistance resources. These are not cash grants; they are the scaffolding that turns a strong scientific idea into a fundable application, which is exactly where most first-time submissions fall short.
Find the right NIH Institute for your technology in 60 seconds
Run the GrantProbe funding finder. Pick your health-technology area and company stage, and get the most-likely funding Institutes, the right SEED resources, and the next receipt date to target.
Open the funding finder โ
How do you apply for an NIH SBIR grant?
Applying for an NIH SBIR grant is a registration-heavy, Institute-targeted process where the specific aims page does the heavy lifting. Here is the path that works for a first-time applicant.
- Register in SAM.gov and eRA Commons. Obtain a Unique Entity ID (UEI) in SAM.gov, then register the small business and the principal investigator in eRA Commons. Start 4 to 6 weeks out.
- Pick the Institute and the opportunity. Use SEED's funding considerations to choose the Institute, then confirm an active parent SBIR/STTR notice or topic NOFO is open.
- Email a program officer. Send a short description and ask whether your aims fit the Institute's mission; this five-minute step prevents months of misrouted effort.
- Write specific aims, then the research strategy. Make every specific aim measurable and tie the proposal to the published review criteria, with a commercialization plan scaled to the phase. Expect study section reviewers to weigh feasibility and significance most heavily.
- Build a justified budget within the guideline. Keep within $323,090 (Phase I) or $2,153,927 (Phase II) unless the Institute confirms a waiver; justify every line.
- Submit before the receipt date. Submit via Grants.gov and validate in eRA Commons before the standard receipt date, with buffer for corrections.
Why do NIH SBIR applications get rejected?
NIH study sections see the same avoidable mistakes every cycle. Each is fixable before submission.
A strong proposal routed to an Institute whose mission does not fit, or scored by a study section that lacks the right expertise, underperforms regardless of quality.
"Develop an innovative platform" is not a specific aim. Reviewers score against measurable milestones, and fuzzy aims read as unfundable risk.
NIH weights commercial potential heavily, especially at Phase II. A proposal that is all science and no market loses points it cannot recover.
Submitting above $323,090 or $2,153,927 without confirming a waiver applies signals the applicant did not read the rules.
SAM.gov and eRA Commons registrations expire and renewals take weeks. A lapse at the receipt date blocks submission with no extension.
NIH-funded biotech founders face a distinctive tax and equity picture: grant income is generally taxable revenue, qualified small business stock treatment can interact with how the company is capitalized, and R&D credits add another layer. Our colleagues at CeoCult cover deductions and grant-income treatment for founders managing federal awards.
Frequently asked questions
How much is an NIH SBIR Phase II grant in 2026?
What are the NIH SBIR standard receipt dates?
What is the NIH SEED program?
What is the difference between NIH SBIR and STTR?
What is an NIH payline and how does it affect SBIR funding?
Bottom line
NIH is the deepest federal source of non-dilutive capital for health startups, but it rewards founders who treat it as a system rather than a single grant. Climb the ladder deliberately: lean on SEED for your first submission, target the Institute whose mission and payline fit your work, write measurable aims, keep the budget within the $323,090 Phase I and $2,153,927 Phase II guidelines unless a waiver applies, and submit before the September 5, 2026 receipt date. Layer Phase IIB and commercialization support once you are in. For the cross-agency SBIR picture, see our DOE small business grants guide and NSF SBIR Phase II guide, and run our grant finder to identify your NIH Institute.
- NIH SEED, Understanding SBIR and STTR (2026 Phase I $323,090 and Phase II $2,153,927 guidelines; September 5, 2026 standard receipt date) verified 2026-05-29.
- NIH Office of Extramural Research, SBIR/STTR (program policy, Fast-Track, Phase IIB).
- NIH eRA Commons (registration and submission system).
- SBIR.gov (program basics, SBA statutory award guidelines, agency comparison).
- U.S. Small Business Administration (SBIR/STTR statutory guidelines and waiver authority).